Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

JABBOUR, ELIAS JOSEPH

One or more keywords matched the following items that are connected to JABBOUR, ELIAS JOSEPH

Item Type	Name
Academic Article	Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients?
Concept	Hypereosinophilic Syndrome
Concept	Down Syndrome
Concept	Sweet Syndrome
Concept	Systemic Inflammatory Response Syndrome
Concept	Myelodysplastic Syndromes
Academic Article	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
Academic Article	Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.
Academic Article	Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Academic Article	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article	PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Academic Article	Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Academic Article	Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Academic Article	Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Academic Article	Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
Academic Article	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Academic Article	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Academic Article	Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.
Academic Article	Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Academic Article	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Academic Article	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article	Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
Academic Article	Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Academic Article	Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
Academic Article	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Academic Article	Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Academic Article	Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
Academic Article	Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Academic Article	Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
Academic Article	New agents in myelodysplastic syndromes.
Academic Article	Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Academic Article	Clinical activity of tipifarnib in hematologic malignancies.
Academic Article	New agents in myelodysplastic syndromes.
Academic Article	Current and future management options for myelodysplastic syndromes.
Academic Article	Thrombocytopenia in patients with myelodysplastic syndromes.
Academic Article	Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
Academic Article	Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Academic Article	Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
Academic Article	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Academic Article	Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Academic Article	Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Academic Article	Clofarabine in the treatment of myelodysplastic syndromes.
Academic Article	2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Academic Article	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Academic Article	Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Academic Article	Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Academic Article	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Academic Article	Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
Academic Article	Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure.
Academic Article	Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
Academic Article	The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Academic Article	A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
Academic Article	Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
Academic Article	Treating myelodysplastic syndrome when hypomethylating agents stop working.
Academic Article	Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.
Academic Article	Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
Academic Article	Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Academic Article	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Academic Article	Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Academic Article	A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Academic Article	Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Academic Article	Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.
Academic Article	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Academic Article	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Academic Article	Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Academic Article	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.
Academic Article	A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
Academic Article	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Academic Article	IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
Academic Article	Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia
Academic Article	Deacetylase inhibitors for the treatment of myelodysplastic syndromes
Academic Article	Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
Academic Article	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents
Academic Article	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
Academic Article	The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes
Academic Article	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs)
Academic Article	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Academic Article	A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
Academic Article	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME)
Academic Article	Decitabine in myelodysplastic syndromes
Academic Article	A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
Academic Article	Phase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome
Academic Article	Unraveling Myelodysplastic Syndromes
Academic Article	Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes
Academic Article	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents
Academic Article	Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents
Academic Article	Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure
Academic Article	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
Academic Article	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Academic Article	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Academic Article	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Academic Article	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Academic Article	Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents.
Academic Article	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Academic Article	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Academic Article	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
Academic Article	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Academic Article	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.
Academic Article	Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Academic Article	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Academic Article	Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.
Academic Article	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
Academic Article	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Academic Article	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Academic Article	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Academic Article	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article	Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Academic Article	Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes.
Academic Article	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Academic Article	Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.
Academic Article	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Academic Article	Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.
Academic Article	Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Academic Article	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Academic Article	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.
Academic Article	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Academic Article	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Academic Article	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Academic Article	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Academic Article	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
Academic Article	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.
Academic Article	Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
Academic Article	Treating Leukemia in the Time of COVID-19.
Academic Article	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia.
Academic Article	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Academic Article	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
Academic Article	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
Academic Article	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Academic Article	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Academic Article	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
Academic Article	Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Academic Article	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Academic Article	Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Academic Article	ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
Academic Article	Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Academic Article	PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
Academic Article	Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses.
Academic Article	A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Academic Article	Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Academic Article	Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Academic Article	Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Academic Article	Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Academic Article	Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Academic Article	Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.

Search Criteria

Syndrome